13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • ROCHE CUP MX39795

    Acronym: 

    CUPISCO

    ACTRN/NCT /ethics: 

    NCT03498521

    Scientific title: 

    A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site

    Summary of trial and patient characteristics

    Cancer Type All cancers
    Trial Type Treatment
    Phase Phase II Tumour Stream Cancer of unknown primary site
    Age Range 18 years and older Cancer Stage All stages
    Sex Both Anticipated Start Date 2018-07-10
    Molecular Target Anticipated End Date 2022-06-25
    Cancer Type All cancers
    Trial Type Treatment
    Phase Phase II
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Cancer of unknown primary site
    Cancer Stage All stages
    Anticipated Start Date 2018-07-10
    Anticipated End Date 2022-06-25

    Trial Summary

    This study will compare the efficacy and safety of molecularly-guided therapy versus standard platinum-containing chemotherapy in participants with cancer of unknown primary site (CUP; non-specific subset) who have achieved disease control after 3 cycles of first-line platinum doublet induction chemotherapy.

    Lay Summary

    A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site

    Sponsor / Cooperative group

    Hoffmann-La Roche

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Flinders Medical Centre Alex Scott-Hoy alex.scott-hoy@sa.gov.au 08 8204 4830 Ganessan Kichenadasse Recruiting